Virtual Library
Start Your Search
Q. Chen
Author of
-
+
P2.03a - Poster Session with Presenters Present (ID 464)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Advanced NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P2.03a-005 - A Study of Endostar Combined with Gemcitabine in the First-Line Treatment of the Elderly Patients with Advanced Non-Small Cell Lung Cancer (ID 5733)
14:30 - 14:30 | Author(s): Q. Chen
- Abstract
Background:
To observe the efficacy and safety of recombinant human endostatin (Endostar) combined with single-agent gemcitabine in the first-line treatment of the elderly patients with advanced non-small cell lung cancer (NSCLC)
Methods:
A total of 118 elderly patients with advanced NSCLC confirmed by pathology in Fuzhou Pulmonary Hospital ofFujian from Oct., 2007 to Sep., 2012 were randomly divided into treatment group and control group. Treatment group (n=62) was given the regimen of Endostar combined with single-agent gemcitabine, while control group only given the regimen of single-agent gemcitabine. After two cycles of chemotherapy, the efficacy was evaluated according to RECIST, and median time to tumor progression, median survival and 1-year survival rate in two groups were recorded. Besides, adverse reactions were evaluated every cycle based on NCICTC (version 3.0).
Results:
Sixty-two patients in treatment group completed more than two cycles of Endostar combined with chemotherapy.There were 11 cases with partial remission (PR), 36 with stable disease (SD)and 15 with progressive disease (PD). There was no statistical significance between two groups by comparison to the overall response rate (ORR) (17.7% vs.10.7%, P=0.278), but significant differences were presented by comparison to the disease control rate (DCR) (75.8% vs. 57.9%, P=0.031) and median progression-free survival (mPFS) (4.0 months vs. 3.7 months, P=0.027). Compared with the median overall survival (mOS), there was no statistical significance(9.1 months vs. 8.5 months, P=0.418). The incidence of myelosuppression among adverse reactions was higher, main in phase G~1/2~ and G~3/4~. In the aspect of hematotoxicity, non-hematotoxicity and biochemical indexes, there was also no statistical significance between two groups (P>0.05).
Conclusion:
Endostar combined withsingle-agent gemcitabine has certain anti-tumor activity, better DCR and highersafety as well as clinical benefit rate for elderly patients with advanced NSCLC, which may be a promising regimen for the elderly patients with advanced NSCLC.
